EA201492260A1 - Вакцина - Google Patents

Вакцина

Info

Publication number
EA201492260A1
EA201492260A1 EA201492260A EA201492260A EA201492260A1 EA 201492260 A1 EA201492260 A1 EA 201492260A1 EA 201492260 A EA201492260 A EA 201492260A EA 201492260 A EA201492260 A EA 201492260A EA 201492260 A1 EA201492260 A1 EA 201492260A1
Authority
EA
Eurasian Patent Office
Prior art keywords
relates
combinations
new
administrations
elicit
Prior art date
Application number
EA201492260A
Other languages
English (en)
Inventor
Ларс Хеие
Анкер Лундемосе
Матс Эквист
Арнт Ове Ховден
Мая Соммерфельт Гренвольд
Видар Вендель Хансен
Биргер Серенсен
Original Assignee
Бионор Иммуно Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бионор Иммуно Ас filed Critical Бионор Иммуно Ас
Publication of EA201492260A1 publication Critical patent/EA201492260A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Изобретение относится к новым комбинациям активных агентов и способам лечения ретровирусных инфекций, включая ВИЧ-инфекции и СПИД. В частности, изобретение относится к новому применению введений и комбинациям соединения, стимулирующего гуморальный иммунитет, и/или пептидов, которые вызывают клеточно-опосредованный иммунный ответ у субъекта; и иммуномодулирующих соединений и/или очищающих резервуар агентов, таких как ингибиторы гистондеацетилазы.
EA201492260A 2012-06-06 2013-06-06 Вакцина EA201492260A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656242P 2012-06-06 2012-06-06
US201361768905P 2013-02-25 2013-02-25
PCT/EP2013/061752 WO2013182662A1 (en) 2012-06-06 2013-06-06 Vaccine

Publications (1)

Publication Number Publication Date
EA201492260A1 true EA201492260A1 (ru) 2015-08-31

Family

ID=48577074

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492260A EA201492260A1 (ru) 2012-06-06 2013-06-06 Вакцина

Country Status (13)

Country Link
US (2) US10335482B2 (ru)
EP (3) EP2858665A1 (ru)
JP (1) JP2015520179A (ru)
KR (1) KR20150029678A (ru)
CN (1) CN104717974A (ru)
AU (2) AU2013273483A1 (ru)
CA (2) CA2874936A1 (ru)
EA (1) EA201492260A1 (ru)
HK (3) HK1207829A1 (ru)
IL (1) IL235890A0 (ru)
IN (1) IN2014KN02774A (ru)
MX (1) MX2014014668A (ru)
WO (2) WO2013182660A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
JP6382831B2 (ja) 2012-11-30 2018-08-29 サンフォード−バーンハム メディカル リサーチ インスティテュート アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
CN104069106A (zh) * 2013-03-27 2014-10-01 南通瑞思医药技术有限公司 苯甲酰胺类化合物在制备激活潜伏艾滋病病毒药物中的应用
WO2015086738A2 (en) * 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine
EP3082799B1 (en) * 2013-12-17 2021-04-28 Versitech Limited Use of isoflavones for the treatment of retroviral infection
WO2015110659A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
CA2936335A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Dosage regimen for hiv vaccine
CA2936139A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Method for the vaccination against hiv
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
CA2951616A1 (en) * 2014-07-11 2016-01-14 Bionor Immuno As Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
US9732119B2 (en) * 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) * 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) * 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
CN105878231A (zh) * 2015-01-26 2016-08-24 复旦大学 黄酮类化合物在制备抗hiv潜伏的治疗药物中的用途
US20180169108A1 (en) * 2015-02-20 2018-06-21 The Johns Hopkins University Drug Combinations For the Treatment of HIV
JP2018515603A (ja) * 2015-05-04 2018-06-14 ビオノル・イムノ・アクシェセルスカプＢｉｏｎｏｒ Ｉｍｍｕｎｏ ＡＳ Ｈｉｖワクチン用の投薬レジメン
WO2017060524A1 (en) * 2015-10-09 2017-04-13 4Sc Ag (e)-n-(2-aminophenyl)-3-(1-((4-(1-methyl-1h-pyrazol-4-yl)phenyl)sulfonyl)-1h-pyrrol-3-yl)acrylamide for the treatment of latent viral infections
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
EP3402483B1 (en) 2016-01-15 2023-11-08 American Gene Technologies International Inc. Methods and compositons for the activation of gamma-delta t-cells
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
US10143746B2 (en) * 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
JP7017247B2 (ja) 2016-03-09 2022-02-08 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド がんを処置するための組み合わせベクターおよび方法
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
IL300730A (en) 2016-07-08 2023-04-01 American Gene Tech Int Inc Pre-HIV vaccine and immunotherapy
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
CN106563124A (zh) * 2016-10-19 2017-04-19 广西大学 硫辛酸作为疫苗佐剂的应用
CA3057142A1 (en) 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
KR20220034736A (ko) 2019-05-31 2022-03-18 비락타 서브시디어리 인크. 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법
CN110423723A (zh) * 2019-07-18 2019-11-08 南方医科大学南方医院 一种外周血b细胞系的构建方法及其应用
CN117042776A (zh) * 2021-03-31 2023-11-10 赛乐隆治疗有限公司 疫苗佐剂

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
AU6713287A (en) 1986-01-06 1987-07-09 F. Hoffmann-La Roche & Co. Expression of htlv-iii gag-gene
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4925784A (en) 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
GB8629116D0 (en) 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
EP0356007A3 (en) 1988-07-22 1991-07-03 Medical Research Council Antigenic determinants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5697151A (en) 1995-08-07 1997-12-16 General Electric Company Method for repairing partitions of a turbine diaphragm
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
PT925294E (pt) 1996-07-24 2003-04-30 Celgene Corp 2-(2,6-dioxopiperidin-3-il)-ftalimidas e -1-oxoisoindolinas substituidas e metodo de reducao dos niveis de tnf-alfa
CA2262906C (en) 1996-08-12 2006-10-31 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
CA2288992C (en) 1997-04-30 2012-06-12 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101501T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı.
HUP0103976A3 (en) 1998-10-05 2008-04-28 Pharmexa As Novel methods for therapeutic vaccination
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
TR200102688T2 (tr) 1999-03-18 2002-01-21 Celgene Corporation İkameli 1-okso ve 1,3-dioksoizoindolinler ve enflamatuar sitokin seviyelerinin azaltılması için farmasötik bileşimlerde kullanımları.
ATE425177T1 (de) * 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
US8715677B2 (en) 2005-09-01 2014-05-06 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
CN101626763A (zh) * 2006-12-06 2010-01-13 北海道公立大学法人札幌医科大学 使用组蛋白脱乙酰酶（hdac）抑制物的细胞免疫增强
BR112012000032A2 (pt) 2009-07-03 2016-03-15 Bionor Immuno As meios terapêuticos e diagnósticos inovadores
US20110245154A1 (en) * 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
WO2012051492A2 (en) 2010-10-14 2012-04-19 University Of Georgia Research Foundation, Inc. Compounds and methods for inhibiting hiv latency
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
ES2711086T3 (es) 2011-10-03 2019-04-30 Univ Bruxelles Reactivación de la expresión génica del VIH-1 para tratar la infección persistente por VIH

Also Published As

Publication number Publication date
AU2013273481B2 (en) 2018-04-05
US10335482B2 (en) 2019-07-02
EP2858667A1 (en) 2015-04-15
EP3967323A2 (en) 2022-03-16
MX2014014668A (es) 2015-03-19
JP2015520179A (ja) 2015-07-16
KR20150029678A (ko) 2015-03-18
IL235890A0 (en) 2015-01-29
HK1207829A1 (en) 2016-02-12
HK1208150A1 (en) 2016-02-26
US20150174235A1 (en) 2015-06-25
AU2013273483A1 (en) 2014-12-11
IN2014KN02774A (ru) 2015-05-08
CA2875624A1 (en) 2013-12-12
CN104717974A (zh) 2015-06-17
EP3967323A3 (en) 2022-05-04
WO2013182660A1 (en) 2013-12-12
EP2858665A1 (en) 2015-04-15
CA2874936A1 (en) 2013-12-12
US20150132255A1 (en) 2015-05-14
AU2013273481A1 (en) 2014-12-18
HK1207967A1 (en) 2016-02-19
WO2013182662A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
EA201492260A1 (ru) Вакцина
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
PH12017500207B1 (en) Indoles for use in influenza virus infection
EA201592048A1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
PH12015500361A1 (en) Methods for the treatment of hepatitis b and hepatitis d infections
EA202090699A3 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MD3250182T2 (ro) Compoziții dispersabile
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
EA201892003A1 (ru) Лечение атопического дерматита собак
WO2015086738A3 (en) Hiv vaccine
GB2515222A (en) Use of flagellin as a vaccine
GB201112587D0 (en) Vaccine
WO2013173256A3 (en) New and improved influenza vaccines
EA201500770A1 (ru) Поливалентная вакцина против гриппа на основе гибридного белка
EA201690551A1 (ru) Применение гидроксипропил хитозана для лечения онихомикоза
PH12017500928B1 (en) A rabies composition comprising pika adjuvant